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PHH) but it would be an oversimplification to assign the differences
in. outcome to these facts.
Although treating hydrocephalus is all that can be done, it is
certainly not all that is wrong in infants with PHH. Lipscomb et al
chose to be optimistic about "early" intervention on the basis of
good developmental quotients. However, hydrocephalus as an
isolated problem is unlikely to produce problems with intelligence. 4
Animal studies also support the notion that the cortical layer is
spared in hydrocephalus. Thus there is no theoretical reason to
suppose "early" treatment of hydrocephalus is the reason for the
difference between previous studies of PHH and that of Lipscomb
et al. It is more likely that their series did not include infants with
significant hypoxic-ischaemic insults. Our series did: two infants
with PHH are microcephalic following shunting5-both had intra-
parenchymal haemorrhage affecting the white matter of one
hemisphere, though we had no suspicion of cortical insults until
follow-up.
How the extent of hypoxic-ischaemic insult should be assessed in
premature babies with PVH remains unanswered. As Volpe et al5
have shown by positron emission tomography, hypoxic-ischaemic
damage may be more extensive than the size of the haemorrhage
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. SIR,-Like Dr Mammel and colleagues (June 18, p 1356) we have
used dexamethasone to treat apparently end-stage broncho-
pulmonary dysplasia, though in an uncontrolled manner, in six
infants over the past two years. Our criteria for treatment were
almost identical to those of Mammel et al and also included
hypercapnia (PaC02 >60 mm Hg) despite peak inspiratory
pressures greater than 30 cm water and intermittent mandatory
ventilation greater than 30 breaths/minute. We used a higher dose
(2 - 0 mg/kg daily) but a shorter duration of therapy (four doses,
given every 12 h over 2 days). All our patients were on parenteral
antibiotics at the time of steroid administration.
Our results confirm the experience of Mammel et al with respect
to acute improvement in respiratory status. Five of the six infants
had prompt increases in Pa02, and reduction in PaC02 and
ventilator support requirements (peak inspiratory pressure and
rate). Improvements were generally noted about 12 h after the first
dose.
There was a concomitant occurrence of brisk diuresis in the five
patients who responded to the dexamethasone. These infants had
also been treated with diuretics and bronchodilators before the
steroid, but these agents had not produced a similar effect. As
Mammel et al suggest, two mechanisms of action may be reduction
of pulmonary oedema and stabilisation of cell membranes.
The absence of subsequent sepsis in our six patients may be a
reflection of antimicrobial therapy, shorter duration of treatment,
or other factors.
The encouraging short-term benefits should lead to a more
extensive controlled trial to evaluate the safety and efficacy of the
drug in these patients, who are at high risk for morbidity and death.
Section of Newborn Services,
Department of Pediatrics,
University of Michigan Hospitals,
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CAN NIFEDIPINE PROVOKE MENORRHAGIA?
SIR,-A 46-year-old woman presented with atypical chest pain.
Investigations, including coronary angiography, were negative.
Nifedipine 10 mg three times daily was prescribed and previous
drugs (thyroxine 0 - 2 mg daily, bendrofluazide 5 mg daily) were
continued. The nifedipine was withdrawn after 3 weeks because it
produced tremor and generalised flushing. The patient’s menstrual
cycle had previously been regular (5/28 days), but within a week of
starting nifedipine she had heavy vaginal bleeding which lasted for 5
weeks. Thereafter her menstrual cycle returned to normal and
remained normal for 4 months. Nifedipine 10 mg three times daily
was then reintroduced; it was withdrawn after 1 week because it
again produced tremors and flushing and because, within a few
days, the patient had a recurrence of heavy vaginal bleeding. The
bleeding lasted for 4 weeks. Her menstrual cycle has since returned
to normal.
A woman aged 44 presented with atypical chest pain. Results of
exercise tests were equivocal. She has been treated with nifedipine
10 mg three times daily. Her menstrual cycle was previously regular
(3/28 days), but since she started nifedipine 3 months ago her
periods have been frequent and heavy (5/20 days). Blood count and
coagulation screen are normal. Gynaecological assessment is
planned.
While we have no proof, it seems likely that nifedipine provoked
the menorrhagia in these patients. The underlying mechanism may
have been local vasodilatation rather than disordered coagulation.
Medical Unit,
Monklands District General Hospital,




MONOCYTE PROCOAGULANT ACTIVITY IN
HYPEREOSINOPHILIC SYNDROME
SIR,-As stated in your June 25 editorial (p 1417) patients with the
hypereosinophilic syndrome (HES) are at increased risk of
thromboembolic complications and experience the consequences of
fibrin deposition, particularly in the myocardial cavity and in large
vessels. The pathogenesis of these complications, and of HES itself,
remains unknown.
Recent evidence suggests that white blood cells might be involved
in intravascular and/or extravascular fibrin deposition by producing
procoagulant activities capable of triggering blood coagulation. 1,2
We have studied the procoagulant activity (PCA) of white blood
cells in a 54-year-old man with HES, with heart, lung, skin, and
gastrointestinal involvement demonstrable both clinically and by
investigation. Polymorphonuclear cells and mononuclear cells were
isolated3,4 and PCA was measured before and after incubation with
a standardised stimulus (Salmonella enteritidis endotoxin, Illg/ml,
4 h at 37&deg;C). The patient’s polymorphonuclear cells (containing
more than 75% eosinophils) lacked PCA (<0-5 thromboplastin
units/104 cells) and did not develop any activity after incubation
with endotoxin. Among normal white cells, monocytes are the
source of PCA, but our patient’s monocytes, studied on three
separate occasions over 1 month, generated, upon endotoxin
stimulation, much more PCA than did monocytes from controls
(150-240 versus 35-62 units/104 monocytes).
During therapy with vincristine and prednisone monocyte PCA
fell; the ratio between the patient’s PCA and the PCA of a control
tested simultaneouslv dropped from 4’0 0 to 1’ 5. This paralleled a
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